M&A Deal Summary

EPI Health Acquires RHOFADE

On October 10, 2019, EPI Health acquired life science company RHOFADE from Aclaris

Acquisition Highlights
  • This is EPI Health’s 1st transaction in the Life Science sector.
  • This is EPI Health’s 1st transaction in the United States.
  • This is EPI Health’s 1st transaction in Pennsylvania.

M&A Deal Summary

Date 2019-10-10
Target RHOFADE
Sector Life Science
Buyer(s) EPI Health
Sellers(s) Aclaris
Deal Type Divestiture

Target

RHOFADE

Malvern, Pennsylvania, United States
RHOFADE cream is a prescription medicine used on the skin (topical) to treat ongoing facial redness due to rosacea in adults.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

EPI Health

Charleston, South Carolina, United States

Category Company
Founded 2017
Sector Life Science
DESCRIPTION

EPI Health is an established dermatology specialty company that has launched and markets innovative prescription therapies to dermatologists to improve patients’ quality of life. It is one of the fastest-growing companies in the US dermatology community. EPI Health was founded in 2017 and is based in Charleston, South Carolina.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1

Seller(S) 1

SELLER

Aclaris

Wayne, Pennsylvania, United States

Category Company
Founded 2012
Sector Life Science
Employees61
Revenue 19M USD (2024)
DESCRIPTION

Aclaris is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris was founded in 2012 and is based in Wayne, Pennsylvania.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-08 Confluence Life Sciences

Saint Louis, Missouri, United States

Confluence Life Sciences, Inc. is a privately held biotechnology company focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. Confluence Life Sciences was founded in 2010 and is based in Saint Louis, Missouri.

Buy $10M